Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Glenmark Pharmaceuticals expands its oncology franchise in India with the launch of Helsinn’s AKYNZEO®, a combination drug for the prevention of chemotherapy-induced nausea and vomiting (CINV)

Glenmark Pharmaceuticals
Posted on: 12 Jul 18
  • AKYNZEO® was developed by Helsinn and Glenmark has the exclusive marketing rights for the product in India and Nepal under a licensing agreement with Helsinn
  • AKYNZEO®, an oral fixed combination of netupitant 300mg and palonosetron 0.5mg, is a single capsule that acts on dual pathway and offers 5-day prophylaxis from both the acute and delayed phases of CINV

Lugano, Switzerland and Mumbai, India, July 9, 2018: Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and Glenmark Pharmaceuticals Ltd, a research-led global integrated pharmaceutical company, today announced the launch of AKYNZEO®, a fixed combination drug for the prevention of chemotherapy-induced nausea and vomiting (CINV), on to the Indian market under an exclusive licensing agreement with Helsinn.

AKYNZEO®, an oral fixed combination of netupitant 300mg and palonosetron 0.5mg, is to be administered in a single capsule that acts on both the two main pathways associated with acute and delayed phases of CINV. The product has been developed by Helsinn and Glenmark has exclusive marketing rights for AKYNZEO® in India and Nepal.

“Oncology is a key area of focus for Glenmark, and we are committed to bringing in new treatment options for Indian patients. Nausea and vomiting associated with chemotherapy has a significant impact on quality of life of cancer patients that can influence a patient’s adherence to the treatments being undertaken. AKYNZEO® is a convenient single-dose for each chemotherapy cycle oral capsule with an activity that covers both the acute and delayed phase of CINV, avoiding multiple drug antiemetic options and thereby improving patient compliance,” said Sujesh Vasudevan, President – India Formulations, Middle East and Africa at Glenmark.

 

 

 

Riccardo Braglia, Helsinn Group Vice Chairman and CEO, commented: “We are very pleased to announce that the oral fixed combination AKYNZEO® has now been launched in India and Nepal, providing a new prophylactic option for patients suffering from chemotherapy-induced nausea and vomiting. Helsinn is focused on helping people with cancer get the best out of every day and is pleased to be expanding its availability. Glenmark is a trusted partner with an excellent footprint in this region and a commitment to providing the best treatment options for people with cancer and we are delighted to be working alongside them on this.”  

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 12/07/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.